PH26104A - Aryl-substituted naphthyridine and pyrodopyrazine derivatives - Google Patents
Aryl-substituted naphthyridine and pyrodopyrazine derivatives Download PDFInfo
- Publication number
- PH26104A PH26104A PH35116A PH35116A PH26104A PH 26104 A PH26104 A PH 26104A PH 35116 A PH35116 A PH 35116A PH 35116 A PH35116 A PH 35116A PH 26104 A PH26104 A PH 26104A
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- carbon atoms
- mammal
- phenyl
- formula
- Prior art date
Links
- 150000005054 naphthyridines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 37
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 25
- -1 -CFj3 Chemical group 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229940114079 arachidonic acid Drugs 0.000 description 8
- 235000021342 arachidonic acid Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 206010006482 Bronchospasm Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 150000007522 mineralic acids Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000002052 anaphylactic effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 4
- 229940043234 carbomer-940 Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003930 superacid Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- WKYRBKKTPWIHNV-UHFFFAOYSA-N 1-phenyl-4-prop-2-enoxy-1,8-naphthyridin-2-one Chemical compound C12=NC=CC=C2C(OCC=C)=CC(=O)N1C1=CC=CC=C1 WKYRBKKTPWIHNV-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SGRODURINDARRU-UHFFFAOYSA-N 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane Chemical compound C1=CC(OC)=CC=C1P1SP(C=2C=CC(OC)=CC=2)S1 SGRODURINDARRU-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NFHIDJHLHNNFFZ-UHFFFAOYSA-N 2-(hydroxymethyl)-4-phenyl-1,2-dihydrocyclobuta[c][1,8]naphthyridin-3-one Chemical compound OCC1CC(C2=CC=CN=C22)=C1C(=O)N2C1=CC=CC=C1 NFHIDJHLHNNFFZ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- MHYYNQWTTVNJGB-UHFFFAOYSA-N 2h-1,8-naphthyridin-3-one Chemical compound N1=CC=CC2=CC(=O)CN=C21 MHYYNQWTTVNJGB-UHFFFAOYSA-N 0.000 description 1
- WGPAKDJMVNGMQT-UHFFFAOYSA-N 3-butyl-3-methoxy-1-phenyl-1,8-naphthyridine-2,4-dione Chemical compound C12=NC=CC=C2C(=O)C(CCCC)(OC)C(=O)N1C1=CC=CC=C1 WGPAKDJMVNGMQT-UHFFFAOYSA-N 0.000 description 1
- JLZALTSJCUTKBP-UHFFFAOYSA-N 3-butyl-4-hydroxy-1-phenyl-1,8-naphthyridin-2-one Chemical compound O=C1C(CCCC)=C(O)C2=CC=CN=C2N1C1=CC=CC=C1 JLZALTSJCUTKBP-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- QVMZFKFGQDVPLG-UHFFFAOYSA-N 4-hydroxy-1-phenylspiro[4h-1,8-naphthyridine-3,1'-cyclopentane]-2-one Chemical compound OC1C2=CC=CN=C2N(C=2C=CC=CC=2)C(=O)C11CCCC1 QVMZFKFGQDVPLG-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- QPYPBNRHDGXJMA-UHFFFAOYSA-N 4h-1,8-naphthyridin-3-one Chemical compound C1=CN=C2N=CC(=O)CC2=C1 QPYPBNRHDGXJMA-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GKFJEDWZQZKYHV-UHFFFAOYSA-N borane;2-methylpropan-2-amine Chemical compound B.CC(C)(C)N GKFJEDWZQZKYHV-UHFFFAOYSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005164 penile vein Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Description
wy oo
PATENT
: » CASE 2408X 26104 1 sc 4B T : ARYL-SUBSTITUTED NAPHTHYRIDI E = 2 i AND PYRIDOPYRAZINE ony 2 0 2
J »
This invention relates to tricyclic = 2 naphthyridine and pyridopyrazine derivatives and to methods for their preparation.
One aspect of this invention comprises free ho bases and pharmaceutically acceptable salts thereof
I having the structural formula I
JN cor fC 1
N N A
(Rl-t-a2) a
Q wherein:
X represents CH or N; .
A represents O or S; : m is an integer of from 0 to 2; n is an integer of from 0 to 2; rl and R2? are the same or different and each is independently selected from H or alkyl:
W represents a covalent bond or a group selected from -0O-, -S(0) y=, ~NH-, -N(rRY)-, -N(cor%)-, and
BAD ORIGINAL 9
-N(s0,R%) {wherein p is an integer of from 0 to 2 and r4 i is alkyl}:
B represents alkylene having from 2 to 8 /carbon atoms, which alkylene may be optionally substituted with a group selected from -OH, -F, alkyl having from 1 to 4 carbon atoms, -CH,OH, -CHO, -CO,H, -COR3 {wherein R3 is selected from -NHRY, -N(rY), and -OorR%, and rR? is as defined above}, and -CN, with the proviso that OH or F is not on the carbon adjacent to W when W is -0-, AA -NH-, -N(rRY), -N(CORrR%)- or -N(s0,rY). B also may represent an unsubstituted alkylene having one or more double bonds.
Q represents an aryl or an aromatic heterocyclic group which can optionally be substituted with up to 3 substituents Y as defined below: and each Y substituent is independently selected from -OH, hydroxymethyl, alkyl, halo, -NO,, alkoxy, -CFj3, -CN, cycloalkyl, alkynyloxy, alkenyloxy, -S(0) -r4 {wherein r? and p are as defined above}, —co-R> {wherein
RS represents -OH, -NH,, -NHRY, N(R%), or -OR? in which rR? is as defined above}, -0-D-COR? {wherein D represents alkylene having from 1 to 4 carbon atoms and R3 is as defined above}, -NH,, -NHR?, -N(rY), { wherein rR? is as defined above} or -NHCOH.
Compounds of formula I in which W is oxygen or a covalent bond are preferred. Also, A is preferably oxygen, while X is preferably CH. The group -B-W- . preferably represents an alkylene or alkyleneoxy group, ratoranly/ (cy) ee, -(CHy)g~, ~(CH5)30- or -(CH;,)40-. . Other suitable -B-W- groups include -CH(OH)(CH,)3-. -CH,CH(OH) (CHy) 5-, —-(CHy)CH(OH)CHp-, -(CH;,)3CHOH-, ~CH(CH,OH) (CHy) 3=, —CH,CH(CH,OH)CH)=, ~(CH,)3CH(CH,OH) -, -CH(OH) (CHy) 4=, -CH,CH(OH)(CH,) 3-, =(CH,),-CH(OH) (CH,) ,-, -(CH,) 3CH(OH)CHy-, -(CH,)4CH(OH)-, -CH(CH,0H)(CHy)4-/ —CH,CH(CH,OH) (CHy) 3—, —(CHy),CH(CH,0H) (CH) 5—,
vo an ~-CH,CH (OH) CH,0-, -CH (CH,0H) (CH,) ,0-, ~CH,CH (CH,0H) CH,0-, : ~- (CH,) ,CH(CH,0H)O-, -CH (OH) (CH,)30~, -CH,CH (OH) (CH,) ,0-, - (CH,) ,CH (OH) CH,0~, ~CH(CH,OH) (CH,) 30-, / ~CH,CH (CH,0H) (CH,) ,0~-, -{CH,) ,CH(CH,0H)CH,0-, and -(CH,) 3CH (CH,0H) O~. The letter n preferably represents zero and m is preferably zero. Q is preferably phenyl or
Y-substituted phenyl, and in the latter case each Y substituent on the Q phenyl ring is preferably selected from chloro, nitro, methoxy or trifluoromethyl. The most preferred orientation for nitro, methoxy and trifluoromethyl substituents is in the meta position.
A preferred subgenus is represented by the formula II
BT \
Ww
XN
: XN NA orf)
IT wherein A, B, W, n and Y are as defined above and gq is 0 to 2.
When utilized herein, the terms below have’ the following scope: halo - represents fluoro, chloro, bromo and . iodo; alkyl (including the alkyl portion of alkoxy) and alkylene - represent straight and branched carbon chains and, unless otherwise specified, contain from 1 to 6 carbon atoms;
alkenyloxy - represents straight and branched carbon chains having at least one carbon to carbon double bond and, unless otherwise specified, contains from 3 to : 6 carbon atoms, the alkenyl group thereof being bonded to an adjacent structural element through an oxygen atom;
alkynyloxy - represents straight and branched carbon chains having at least one carbon to carbon triple bond and, unless otherwise specified, contains from 3 to 6 carbon atoms, the alkynyl group thereof being bonded to an adjacent structural element through an oxygen atom;
cycloalkyl - represents saturated carbocyclic rings having from 3 to 7 carbon atoms;
aryl - represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one benzene ring, with all available substitutable carbon atoms thereof being intended as possible points of attachment to the/ (CRIR?) group or to the N atom if m is zero.
More preferably, aryl is phenyl or Y-substituted phenyl.
Suitable aryl groups include, e.g., phenyl, naphthyl, indenyl, indanyl, 3-chlorophenyl, 4- chlorophenyl, 4-fluorophenyl, etc.;
aromatic heterocyclic - represents cyclic groups having at least one O, S and/or N in the ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups preferably containing from 3 to 14 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or 3-
) furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-imidazolyl, 2-, 4-, 5- or 6-pyrimidinyl, 2- or 3- pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6- i1,2,4- triazinyl)}, 2-, 3-, 4-, 5-, 6- or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 3-, 4- or S5-pyrazolyl, 2-, 4- or 5-oxazolyl, etc., with all available substitutable carbon atoms thereof being intended as a possible point of attachment to the (cR'R?) ny group or to the N atom if m is zero.
— TT _
Cm Co oAyody ok
Tre ag 26104 a
Dr
The invention in its pharmaceutical composi don 3! : aspect comprises a compound as described above in SE combination with a pharmaceutically acceptable carrie jz
The invention also includes a method Eo S 3d treating allergic reactions in a mammal which comprises 3g ti, administering an anti-allergic effective amount of the; : Se above-defined [pharmaceutical composition to the mammal. i
The invention in a second pharmaceutical method aspect is a method for treating inflammation in a mammal which comprises administering an anti-inflammatory effective amount of the above-defined pharmaceutical composition to the mammal.
The invention in a third pharmaceutical method . aspect is a method for treating peptic ulcers in a mammal {© which comprises administering a cytoprotective effective amount of the above defined pharmaceutical composition to the mammal.
The invention in a fourth pharmaceutical me thod aspect is a method for treating hyperproliferative skin : diseases, e.g. psoriasis, lichenified eczema or seborrhoeic dermatitis, in a mammal which comprises topically administering an effective amount of the above- identified pharmaceutical composition to the mammal. . . : £iEth pl fen] hod aspect—is-a—methed for Suppressing—theimmune response—in mammal which comprises—administering—to—a—mammal—in— . need—of such-treatment—an—immunosuppressing—effeetive- : Another aspect of the invention is a method for manufacturing a composition of formula I said method characterized by:
BAD ORIGiinaL o ..
a) treating a compound of formula IV
H OH
X B ) orf Ww
Nn
N N A é (Rl-c-Rr2) m
Q with a superacid having a Hammett activity function of less than minus 12; b) contacting a compound of the formula ( RlOglly cRl2«cpl3plé
Tt
OH
X RS
N ! 0 (Rl-c-a2) =
Q
XI. with a strong organic or inorganic acid to produce compound I; c) contacting a compound of the formula 0 eR Rte . \ R R ; v Ne
N ! 12
X C-R
Y
¢ —
N I 0 1. - 2 (R i R )a qQ
XIV.
FR, - ih # C . a ok “ds du A. Lo. i RRs
EVP ET }
with a strong base to form a compound of formula I; or : d) contacting a compound of the formula
X
»
N \ 0 2 (R-C—R
Q with a reducing agent to produce a compound of the formula ,
J ~
I
N N 0 2 (R=C—R ) 0 Q wherein X, A, m, n, W, B, OQ, Y, rl, Rr? are as previously defined and wherein R® is an alkyl group having from 2 to 8 carbon . atoms; r10, ril, R12, R13 ang r!4 independently are H or an alkyl having from 1 to 4 carbon atoms: r is 0 or 1.
The compounds of formula I contain a -(crIR?) - substituent wherein each Rl! group and each Rr? group may vary independently. Thus, for example, when m equals 2 the following patterns of substitution (wherein hydrogen and CH3 are used to represent any substituent, rl or RZ) are contemplated: -C(CH3) ,CHy~, =CH,C (CH3) 5, ~CH,CH(CH4)-, -CH(CH3)CH,%, -(C(CH3)H),- and the like.
As noted above, the compounds of the invention may include one or two Y substituents on the fused ring system. Also, the Q group may include up to three Y substituents depending upon the available sites for subst tution. In compounds where there is more than one such Y substituent, they may be the same or different.
Thus, compounds having combinations of different Y substituents are contemplated within the scope of the invention. Examples of suitable Y substituents include hydroxy, methyl, chloro, bromo, methoxy, cyclohexyl, allyloxy, 2-propynyloxy, methylthio, methylsulfonyl, carboxy, acetoxy, N-methylaminocarbonyl, acetoxymethoxy, acetylamino, methylsulfonylamino and the like.
Compounds of the invention of formulas I and II can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemihydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms for purposes of this invention.
Certain compounds of the invention may exist in isomeric forms. The invention contemplates all such : isomers both in pure form and in admixture, including racemic mixtures.
Certain compounds of the invention also form : pharmaceutically acceptable salts with organic and inorganic acids, e.g., the pyrido- or pyrazino- nitrogen atoms may form salts with strong acid while compounds having basic Y substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric,
phosphoric, acetic, citric, oxalic, malonic, salicylic, . malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids : well known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the invention.
Also, some compounds of this invention are acidic, e.g., when Y is OH, and can form salts with inorganic and organic bases.
The compounds of this invention may be synthesized from the corresponding 3-spiro-4-keto analogues of formula III below, 0
I.
N } A I1I (Ri-c-rl),
Q which may be synthesized following the procedures . described in U.S. Patent No. 4,762,564 issued March 24, 1987 and in EPO Publication No. 0 144 996, published June 19, 1985. Alternative synthetic routes for the synthesis of these starting materials and substitutional variants thereof may be accomplished by those skilled in the art.
. in . This process involves a selective redyction of
Lé the 4-keto group of the compound of formula TTI! followed i by dehydration and rearrangement in the presence of a : \ strong organic or inorganic acid. In particular, the compound of formula III is selectively reduced at the 4 position using a reducing agent capable of reducing ketones in the presence of an amide function in an acidic medium, e.g., a hydride reducing agent, to produce a compound of formula IV
H_,OH 4X : or CL
Xn N A (l-t_s2
I m 0) iv.
Examples of suitable reducing agents for this step are sodium cyanoborohydride and tert-butylamine borane. For a discussion of such selective reducing agents, see, for example, Herbert C. Brown, Boranes in Organic Chemistry,
Cornell University Press, Ithaca and London, 1972. The reactions may be performed with cooling, with heating or at room temperature, as appropriate for the particular material being treated, e.g. at about 0%¢ to about 40%c. Typically, the reaction is essentially complete in several minutes, but some reactions take several days to obtain maximum yield.
Suitable solvents are those which are capable of dissolving the starting materials and which do not react with the reducing agent to make the solution basic, of which aqueous alcohol and aqueous tetrahydrofuran in combination with a weak mineral or carboxylic acid, such * as acetic acid, are examples.
The compounds according to structural formula . tv ore treated, either in their impure state or after suitable purification using techniques well known to : those versed in the art, e.g., chromatography, with a strong organic or inorganic acid such as H,S0y4, methanesulfonic acid, Eaton's reagent, polyphosphoric } acid, etc., or strongly acidic salts such as NaHSO,.
Superacids having a Hammett acidity function of less than about minus 12, i.e., minus 13, minus 14, etc., provide particularly advantageous results in this process.
Suitable superacids include trifluoromethanesulfonic acid, HF /BF 4, CH3SO03H/BF 3, etc. This measure of acidity is defined in Hammett, Louis P., and Deyup, Alden J.,
Journal of the American Chemical Society, Vol. 54, 1932,
P. 2721. The time and temperature of the reaction can vary depending on the acid employed. For example, with
CF3SO3H as the acid the temperature is generally in the range of from about room temperature (e.g., 25°C.) or below to about 150°C. Lower temperature (e.g., from about -78°C. to about 25°C.) may also be employed with for example HF /BF 3. The acid is also generally used in excess, e.g., in an amount of from about 1.5 to about 30 equivalents. While not wishing to be bound to a specific
Cy mechanism, it appears that this treatment causes : 4 rearrangement of the spiro ring to form the ring ®) <. - with the elimination of water, thus providing compounds of formula I. No diluent is required, but an inert co- solvent, such as a halohydrocarbon, e.g., methylene chloride, may be used.
Certain compounds of the invention can be prepared by an alternative reaction scheme employing as starting materials compounds of the formula Vv
OH
6 2X | XR (Ya . NE ¥ 0 (Rl-c-r?) . Q Vv wherein rl, RZ, Q, X, ¥, m and n are as defined above and
R® is an alkyl group having from 2 to 8 carbon atoms.
Such compounds can be prepared as described in U.S.
Patent No. 4,492,702 or by reaction of a compound of the formula VI with a compound of formula VII.
X ~, coon’ (Y) £ n > T + R6cu,co, RE —eee v
N NH
(cri?) vil
Q vi wherein rl, RZ, RS, Q, X, ¥Y, m and n are as defined above and R’ and R8® are the same or different and are alkyl of from 1 to 8 carbon atoms.
In this alternative method, the compound of formula V is first reacted with an electrophilic halogenating agent, e.g., Bry, I, + KI, ICl, etc., to produce a compound of formula VIII: 0 6
X
Z | 2 aE l_c.p (R i R )a
Q
VIII wherein 2 represents halo. This reaction can be . performed in an inert solvent and at any suitable temperature, preferably, at room temperature or below. . The compound of formula VIII is subjected to a nucleophilic displacement with an alcohol, e.g., an alkdnol such as methanol or an aralkanol such as benzyl alcohol. For example, the compound of formula VIII may be reacted with 1,8-diazobicyclo[5.4.0}undec-7-ene [DBU] and an alcohol, with the alcohol group replacing the halide group to produce a compound of formula IX 0
Ré oo 1 on . wg N 0 (Rlobetd) { qQ
IX wherein R? is the residue of the alcohol, e.g. alkyl group such as methyl or aralkyl group such as benzyl.
This reaction may be conducted in an inert solvent and at any suitable temperature, again preferably at room temperature or below.
The compound of formula IX is reacted with a compound of the formula M-(CcrIORL1) crl2=crl3gl4 {wherein M is an alkali metal such as Li or is Mg-Z where
Z is a halo group: r10, rll, R12, R13 and r!4 may be the same or different and each is selected from B or alkyl having from 1 to 4 carbon atoms: and r is 0 or 1} to . produce a compound of formula X / (culOnlly cplZecaldnl® x OH RS 9 mE | OR
N I 0 l.c-rl (R : R )a
Q
X.
This reaction is performed under conventional conditions, e.g., in an inert solvent such as THF or diethyl ether } and at any suitable temperature up to reflux.
The R? group is then removed with an ether cleaving reagent, e.g., CF3SO3H, BBrj, C,oHgSH and AlClj,
K*C,HgS™ in DMF, Na'C,HgS™ in DMF, etc., under conventional reaction conditions for such reactions to produce a compound of formula XI ( RlOglly crl2acrl3nl® r } H ma oH l.c-n? (R i R )a
Q
XI.
~15~-
The R® alkyl group is eliminated and a . cyclizafion dehydration is effected by use of a strong organic or inorganic acid, such as CF3503H, . polyphosphoric acid, Eaton's reagent, P,0¢ in CHCl, . etc., to produce an alkene from the r® group and a compound of formula XII 2
X x 0 wag
NN N N 0 (R1-c-rY)
Q
XII.
When r is 1, the following isomer may also result: 3glé a R
X XN 0 ‘ wa
Nn " 0 (rl-c-nd)
Q
XIla.
This reaction can be performed neat or with an inert solvent and at any suitable temperature, preferably at room temperature or below. /
In another method similar to that described in . C. Keneko, T. Naito and M. Somei, J.C.S. Chem. Comm., 804 (1979), a compound of formula XIII (crlOplly—cnl2acrlipls . i r } Xx x8 (r)
N I 0 l.c-np? (R | R Ya
Q
XIII
{wherein R}, RZ, r10, rll, R12 R13 R14 oo, x, v, m, n and r are as defined above} can be irradiated with ultraviolet radiation, e.g., about 3000A, to produce a compound of formula XIV 0 ————(cr}%) ¢ vy 13 ald) \ R_ 7 ! ! \ Cl fall x C-R mw. nN
N I 0 (rl-c-rd) : X1v.
The compound of formula XIII is preferably in an inert solvent, 9. an alcohol such as methanol, or methanol/CH,Cl,, and the reaction mixture may be cooled during irradiation, if necessary. The starting compounds of formula XIII can be prepared by the methods described - in U.S. Patent No. 4,492,702.
The compound of formula XIV is reacted with a strong base such as a salt of an alcohol, e.g., a sodium or potassium alkoxide such as NaOCH3, to produce a compound of formula XV all Ale ~ CRORE oR ——R wo. TL, (Rl-t-ad).
Q
Xv.
This last reaction can be conducted in an inert solvent, e.g., an alcohol such as methanol, and at any suitable temperature, preferably at about 75° to about 125°C.
The compounds of this invention wherein A is - sulfur may be obtained by treating the purified 2- carbonyl compound of formula I with thiating reagents well known in the art. Lawesson's Reagent {2,4-bis(4- methoxyphenyl-1,3~-dithia-2,4-diphosphetane-2,4-disulfide} or one of its analogs, in toluene, or phosphorus pentasulfide in pyridine/is suitable for this purpose. } For preparing pharmaceutical compositions from the compounds described by this invention, inert, . pharmaceutically acceptable carriers are admixed with the active compounds. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be one or more substances which may also act
§ 26104 -18- as diluents, flavoring agents, solubilizers, lubricants, . suspending agents, binders or tablet disintegrating agents; it may also be an encapsulating material. : Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for . parenteral injection. Liquid preparations can also be formulated in solution or suspension in aqueous polyethylene glycol solution.
Formulations for topical application may include creams, aerosols, sprays, dusts,. powders, lotions and ointments which are prepared by combining an active ingredient according to this invention with conventional pharmaceutical diluents and carriers commonly used in topical dry, liquid, cream and aerosol formulations.
Ointments and creams may, for example, be formulated with an aqueous or oily base’ with the addition of suitable thickening and/or gelling agents.
Lotions may be formulations with an aqueous or oily base and will, in general, also include one or more of the following, namely, stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes and the like.
Powders may be formed with the aid of any suitable powder base, e.g. talc, lactose, starch, etc.
Drops may be formulated with an aqueous base or non- aqueous base also comprising one or more dispersing ] agents, suspending agents, solubilizing agents, etc.
The topical pharmaceutical compositions according to the invention may also include one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chlorides, etc.
The topical pharmaceutical compositions according to the invention may also contain other active ingredients such as antimicrobial agents, particularly . antibiotics, anesthetics, analgesics and antipruritic agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral } administration. Such liquid forms include solutions, suspensions/and emulsions.
The compounds of the invention may also be deliverable transdermally for systemic distribution. The transdermal compositions can take the form of creams, lotions and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active components.
The compounds of this invention may be employed as anti-allergy agents in the treatment of, for example, 7 asthma, allergic or seasonal rhinitis, and/or chronic
Ld bronchitis. The anti-allergy method of this invention is identified by tests which measure a compound's inhibition of anaphylactic bronchospasm in sensitized guinea pigs having antigen induced broncho-constriction.
In one such test procedure, male Hartley guinea pigs (250-300 g) are sensitized with 5 mg ovalbumin . injected i.p. and 5 mg injected s.c. in 1 ml saline on day 1 and 5 mg ovalbumin injected i.p. on day 4. The - sensitized animals are used 3-4 weeks later at which time they weigh 450-500 g.
The sensitized guinea pigs are fasted overnight and{ the following morning are anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 g/ml diallybarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). The trachea are cannulated and the animals are ventilated by a Harvard® . rodent respirator at 50 strokes/minute with a stroke volume of 5 ml. A side arm to the tracheal cannula is - connected to a pressure transducer (Harvard) to obtain a continuous measure of intratracheal pressure which is recorded on a polygraph (Harvard). The jugular vein is cannulated for the i.v. administration of substances.
The animals are challenged with antigen (0.5% ovalbumin) as an aerosol generated from a DeVilbiss® Model 65 ultrasonic nebulizer and delivered through the tracheal cannula for 30 seconds. Bronchoconstriction is measured as the peak increase in intratracheal pressure occurring within 5 minutes after antigen challenge.
The sensitized guinea pigs are injected i.v. with 1 mg/kg propranolol, 5 mg/kg indomethacin and 2 mg/kg mepyramine given together in a volume of 1 ml/kg.
Fifteen minutes later the animals are challenged with nebulized ovalbumin. Test compounds are administered ’ orally 2 hours before challenge with ovalbumin.
Suppression of anaphylactic bronchospasm is expressed as a percent inhibition of the peak increase in intratracheal pressure by comparison to a vehicle-treated control group.
Four compounds of the invention tested in the above procedure were found to inhibit anaphylactic brochospasm as indicated in Table I below:
Table I 3 \
Ww
Xx -. A
EDg {(p.o.)~in
Compound Y -B~-W- anaphylactic
No. bronchospasm test 1 m-Cl —(CHp) 4- 2 mg/kg . (hemihydrate) H -(CHy) 4- 2 mg/kg
These compounds were also found to inhibit allergen- induced histamine release from guinea pig and human sensitized tissue.
The compounds are effective non-adrenergic, non-anticholinergic, antianaphylactic agents. When administered orally they are active at doses from about 0.5 to 25 mg/kg of body weight, preferably 0.5 to 10 ' . mg/kg; whens administered parenterally, e.qg., intravenously, the compounds are active at dosages of from about 0.1 to 5 mg/kg body weight preferably 0.1 to 2.5, and when administered by inhalation (aerosol or nebulizer) the compounds are active at dosages of about 0.1 to 5 mg per puff, one to four puffs may be taken every 4 hours.
The compounds of this invention are also useful . for the treatment of inflammation. Thus, they are useful in the treatment of arthritis, bursitis, tendonitis, gout : and other physical conditions characterized by inflammation. The anti-inflammatory use of the compounds of this invention may be demonstrated by the Reversed . Passive Arthus Response Technique, as described below.
Reversed Passive Arthus Response (RPAR)
Animals, Materials and Methods
Male Lewis inbred albino rats weighing 180-200 grams obtained from Charles River Breeding Laboratories are used in these experiments. The rats are housed 3 animals/cage and food and water are allowed ad libitum.
The animals are numbered 1-3 in each cage and color marked for identification purposes.
Drug and Reagent Preparation
All reagents and drugs are prepared just prior to the study. Crystallized and lyophilized bovine serum albumin (BSA), available from Sigma Chemical Company, is solubilized without shaking in cold, sterile, pyrogen- free saline (10 mg/ml). Lyophilized anti-bovine serum albumin (IgG fraction), obtained from Cappel
Laboratories, is suspended in sterile distilled water and diluted with cold, pyrogen-free saline (PFS) just prior to use. The final concentration of anti-bovine serum . albumin is 0.5. mg/ml of PFS. Both BSA and anti-BSA solutions are iced during use. Drugs are suspended or - solubilized in an aqueous solution of methyl cellulose : (MC) with an homogenizer just prior to administration.
Drug Administration and Induction of Inflammation
Groups of animals (6/group) are dosed with drug in MC by gavage once daily for 3 days. The last dose is . administered one hour prior to sensitization with BSA.
Controls are given MC alone and a drug-standard is usually included in each assay for verification } purposes. Drugs are prepared and diluted so as to provide a dose for a 200 gram animal which is equivalent to the mg/kg dose for each experiment. Thus each rat : receives an oral dose in a volume of approximately 2.0 cc. One hour after the last dose the animals are lightly anesthetized with ether and "sensitized" by injection of 0.2 ml of PFS containing 1.0 mg of BSA into the penile vein. One hour later, the animals are "challenged" in 7 the right rear paw with subplantar injections fof 0.2 ml of ml of PFS containing 0.1 mg of anti-BSA. Immediately after the subplantar injection, the right paw is dipped (up to the lateral maleolus) into the mercury well of a ) plethysmograph. The volume of mercury displaced is converted to weight and recorded. This value is considered to be the control reading for the animal. Paw volumes are subsequently recorded with a plethysmograph during the development of the inflammation at 2 and 4 hours post-challenge.
Results
Results are expressed by the change in paw volume (A paw volume) from the control reading for each animal to that recorded 2 and 4 hours post-challenge. : All drug treated groups are compared to the MC control for significant differences with an analysis of variance. Differences from control in drug-treated groups are expressed as percent change from control in
Table II.
TABLE II
3 \ -W
I
XN 0
Compound Percent Inhibition
No. x -B-W- Dose(p.o0) vs. Control at 2 hrs. at 4 hrs. 1 mCl -(CHj) 4~ 25 mg/kg 64 30 2 H -(CHy) 4~ 25 mg/kg 75 29 (hemihydrate) 4 H -(CHy40- 25 mg/kg 74 25
On the basis of the test results, an oral dosage range of from about 5 mg/kg of body weight per day to about 50 mg/kg of body weight per day in divided doses taken at about 4 hour intervals is recommended. The dosage to be administered and the route of administration depends upon the particular compound used, the age and general health of the patient and the severity of the inflammatory condition. Thus, the dose ultimately decided upon must be left to the judgment of a trained - health-care practitioner./
The compounds of this invention are also useful ¢ in the treatment of peptic ulcers. They display chemotherapeutic activity which enables them to relieve the symptoms of peptic ulcer disease and stress ulceration, and to promote healing of gastric and/or duodenal ulcers. The antiulcer activity of the compounds of this invention is identified by standard tests which
261.0 measure the cytoprotective effect in rats, e.g., by . inducing gastrointestinal damage with ethanol prior to administering a compound of the invention. The compounds : may be used as conjunctive therapeutic agents for coadministration with such anti-inflammatory/analgesic agents as aspirin, indomethacin, phenylbutazone, ] ibuprofen, naproxen, tolmetin and other agents. The compounds of this invention prevent the untoward side effects of irritation and damage to the gastrointestinal tract caused by such agents.
In the treatment of peptic ulcer disease, and the prevention and treatment of drug-induced gastric ulceration, the active compounds of this invention can be administered in unit dosage forms such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, suppositories, mechanical delivery devices, e.g. transdermal, and the like. The compounds of this invention may be administered at doses of about 0.05 - 50 mg/kg of body weight per day.
Preferably the total dosages ar¢/ administered in 2-4 divided doses per day. :
The compounds of formula I are useful in the treatment of hyperproliferative skin disease, e.g., psoriasis, which utility may be demonstrated by the
Arachidonic Acid Mouse Ear Test as described below.
Arachidonic Acid
Mouse Ear Test,
Materials and Methods
Charles River, female, CD, (SD) BR mice, 6 weeks old, are caged 8/group and allowed to acclimate 1-3 weeks prior to use.
Arachidonic acid (AA) is dissolved in reagent grade acetone (2 mg/.01 ml) and stored at -20°C for a maximum of 1 week prior to use. Inflammatory reactions : are induced by applying 10 ul of AA to both surfaces of one ear (4 mg total). ’ Test drugs are dissolved in either reagent . grade acetone or aqueous ethanol (only if insoluble in acetone) at the same doses selected by Opas et al., Fed.
Proc. 43, Abstract 2983, p. 1927 (1984) and Young et al.,
J. Invest. Dermatol. 82, pp 367-371 (1984). These doses are employed to ensure maximum responses and to overcome any difference in topical absorption which could occur with any drug applied in an aqueous ethanol vehicle. The test drug is applied 30 minutes prior to challenge with
AA. /
The severity of the inflammation is measured as a function of increased ear weight. A 6 mm punch biopsy is removed 1 hour after AA challenge and weighed to the nearest 0.1 mg. Mean % standard error and all possible comparisons are made via Duncan's Multiple Range
Statistic.
As a result of the topical administration of a compound of formula I, a remission of the symptoms of the psoriatic patient, in most cases, can be expected. Thus, one affected by psoriasis can expect a decrease in scaling, erythema, size of the plagues, pruritus and other symptoms associated with psoriasis. The dosage of . medicament and the length of time required for } successfully treating each individual psoriatic patient v may vary, but those skilled in the art of medicine will be able to recognize these variations and adjust the course of therapy accordingly.
Included within the invention are preparation for topical application to the skin whereby the compounds having structural formula I are effective in the
— Ayo gy x 26104 -27- treatment and control of skin diseases characterized by rapid rates of cell proliferation and/or abnormal cell proliferation, e.g. psoriasis. . In a preferred method of carrying out the invention, a pharmaceutical formulation comprising a ’ compound of formula I together with a non-toxic, pharmaceutically /cceptable topical carrier, usually in concentrations in the range of from about 0.001 percent to about 10 percent, preferably from about 0.1 percent to about 5 percent, is applied several times daily to the affected skin until the condition has improved. Topical applications may then be continued at less frequent intervals (e.g. once a day) to control mitosis in order to prevent return of severe disease conditions.
As mentioned in Serial No. 851,068, filed April 11, 1986, the subject compounds possess anti-allergy and anti-inflammatory activities. For example, Compound A
By has an ED35 value of about 0.5 mg/kg p.o. in tests rw! oe measuring the inhibition of anaphylactic bronchospasm in ; . sensitized guinea pigs having antigen-induced i bronchoconstriction and an EDg, value of about 4.5 mg/kg { p.0. in tests measuring the reverse passive Arthus ‘ - reaction in the pleural cavity of rats (as described by © Myers et al., Inflammation, Vol. 9, No.l, 1985, pp. 91- ‘ In all of the above modes of treatment, the dosage to be administered and the route of administration depends upon the particular compound selected, the age and general health of the subject, and the severity and type of condition to be controlled. Thus, the dose ultimately provided must be left to the judgment of a trained health-care practitioner.
The quantity of active compound in a unit dose ’ preparation may be varied or adjusted from 1 mg to 100 mg according to the particular application and the potency ) of the active ingredient and the intended treatment. The . composition may, if desired, also contain other therapeutic agents. - When administered parenterally, e.g. intra- venously, the compounds are administered at a dosage range of about 0.1 to 5 mg/kg of body weight in single or multiple daily doses.
The invention disclosed ‘herein is exemplified by the following preparative examples, which should not be construed to limit the scope of the disclosure.
Alternative mechanistic pathways and analogous structures within the scope of applicants invention, may be apparent to those skilled in the art. . Preparative Example 1 1'-(3-Chlorophenyl)-1',4'-dihydro-4'-hydroxy-spiro[cyclo- pentane-1,3'(2'H)-[1,8]-naphthyridin]-2'-one
To a solution of 2.2 g (6.73 mmol.) of 1'-(3- chlorophenyl)-spiro{cyclopentane-1,3'-[1,8]- naphthyridin)-2',4'-(1'H)dione in 176 mL of (1:1) THF:
EtOH (abs.) was added 2.54 g (40 mmol.) of NaBH3CN and 3.0 mL of acetic acid. The solution was stirred at room - temperature. Af additional 0.2 g (3.2 mmol.) of NaBH;CN and 0.3 mL of acetic acid were added on the fourth day. ’ After 9 days the reaction was stopped by slow addition of mL of water. After concentration, the residue was purified by column chromatography, eluting with CHC14-
CH30H (95:5) to yield a colorless solid, 1.82 g. (5.53 mmol. 82%).
Recrystallization from CHCl3 and diethyl ether . (Et,0) yielded the product, m.p. 144-146°C.
Preparative Example 2 (SR,RS)-1-(3-Chlorophenyl)-4-hydroxy=1,3',4,4',5',6"'- ; hexahydro-spiro[l,8-naphthyridine-3(2H),2' [2H] -pyran}-2- one (Compound A) and (RS,RS)-1-(3-Chlorophenyl)-4- hydroxy-1,3',4,4',5',6'-hexahydro-spiro(1,8,- naphthyridine-3 (2H) ,2'[2H]-pyran]-2-one (Compound B)
To a solution of 1.0 g (2.92 mmol.) of 1-(4- chlorophenyl)-3',4',5',6'-tetrahydro-spiro(1,8- naphthyridine-3,2'-[2H]-pyran]-2,4-dione in 80 mL of (1:1) THF /C,HgOH (abs.) was added 0.734 g (11.66 mmol.) of NaBH3CN and 0.6 mL of acetic acid. The solution was stirred at room temperature for 5 days, then it was quenched by the addition of 5 mL of water. After concentration, the residue was purified by column chromatography over silica gel, eluting with CHC13-CH;O0H (95:5), to yield 1.06 g (95%) of a mixture /of the diastereomers, Compounds A and B. These were separated by preparative reversed-phase HPLC, eluting with CH3CN-
H,0-CH3COOH (30:70:1) to yield 0.52 g (54%) of Compound
A, m.,p. 183-184.5°C, and 0.12 g (12%) of Compound B, m.p. 186.5-188.5°C. . Preparative Example 3 } 4-Hydroxy-1,3',4,4',5',6'-hexahydro-1-phenyl-spiro[1,8- naphthyridine-3(2H),2'[2H]-pyran]-2-one (mixture of diastereomers)
In a stirred mixture of tetrahydrofuran (THF) (200 mL) and CyH.0H (200 mL) was suspended l-phenyl-
3',4',5',6'-tetrahydro-spiro(1,8-naphthyridin-3,2'-[2H]- ’ pyran}-2,4-dione (6.2 g) at room temperature. To the suspension was added acetic acid (2.6 mL) and tert- ) butylamine~borane (3.24 g). . After stirring for about 1 hour, water (ca. 200 mL) was added and the mixture was concentrated under . vacuum to a volume of about 100 mL Additional water (400 mL) was added and the mixture was extracted with methylene chloride. The methylene chloride extract was separated, dried over sodium sulfate, filtered and concentrated. Ether was then added and the mixture was cooled. The resulting solid was removed by filtration, washed with fresh ether and dried to yield the desired product as a mixture of /diastereomers, m.p. 211-213°C.
By the methods described in Preparative
Examples 1-3, the following compounds were prepared: . 1',4'-Dihydro-4'-hydroxy-1'-phenyl-spiro[cyclopentane- 1,3'-(2'H)[1,8)-naphthyridin]}-2'-one, m.p. 148-150°C; and p 1',4'~-dihydro-4"'-hydroxy-1'-phenyl-spirol[ furan-2,3- (2'H)[1,8]-naphythridin}-2'-one, mixture of diastereomers, m.p. 220-222°C.
Example 1 . . 7,8,9,10-Tetrahydro-5-phenyl-benzo[c] [1,8] -naphthyridin- 6- (5H) —one
A solution containing 1.2 g (4.07 mmol.) of : 1',4'-dihydro-4'-hydroxy-1'-phenyl-spiro[cyclopentane- 1,3'(2'H)-[1,8]-naphthyridin]-2'-one in 5.0 mL of trifluoromethanesulfonic acid was stirred at room temperature for 1.75 hours.
To this solution was added 100 mL of water and the resulting solution was adjusted to pH 5.0 with 2N
NaOH. The precipitate was collected by filtration,
Co washed with water, and redissolved in 200 mL of CH,C1,.
The organic solution was washed twice with 50 mL of saturated NaHCO3 solution, then with 100 mL of H,0, dried
Co with Mgs0y,, filtered, and concentrated in vacuo to yield 0.62 g (55%) of material, which was recrystallized from ‘ CHC143/Et,0 to yield/the desired product, m.p. 160-162°C.
Example 2 2,3-Dihydro-6-phenyl-1H-pyrano[2,3,-c} [1,8] -naphthyridin- 5(6H) -one, La H,0
To trifluoromethanesulfonic acid (5.0 mL) was added slowly, in portions, 1',4'-dihydro-4'-hydroxy-1'- phenylspiro[furan-2,3-(2'H)-[1,8]-naphythyridin]-2'-one (1.09) using a solid powder addition funnel, under N, at . room temperature. The reaction was followed by HPLC and
TLC which showed that one diastereomer rearranged faster than the other but that both eventually disappeared, after a total of about 24 hours.
The resulting solution was poured into ice- water (200 mL) containing NaOH (2.26 g). The pH was then adjusted to 4 with 1 N HCl. The precipitate which formed on standing was collected, washed with water and purified by chromatography on silica gel (100 g), eluting with
CHCl, containing 2.5% of methanol, to yield the desired - product, m.p. 250-252°C.
In a similar manner, except for the length of ) time for which the reaction is run (progress followed by
TLC), the following compounds were prepared: 5-(3-Chlorophenyl)-7,8,9,10-tetrahydro-benzofc] [1,8] - naphthyridin-6 (5H) -one, m.p. 133-135°C.; /
7-Phenyl-1,2,3,4-tetrahydro-oxepino[2,3-c][1,8]- : naphthyridin-6 (7H) -one, m.p. 191-193°C.; and 7- (3-Chlorophenyl)-1,2,3,4-tetrahydro-oxepino(2,3- . cl [1,8)}-naphthyridin-6 (7H) -one, m.p. 215-217°C. . Example 3 2,3-Dihydro-6-phenyl-1H-pyrano[2,3-c] {1,8]- naphythyridin-5(6H)-thione.
A suspension of 2,3-dihydro-6-phenyl-1H- pyrano[2,3-c] [1,8] -naphythyridin-5(6H)-one in dry toluene is stirred and heated in an N, atmosphere with a slight excess of Lawesson's Reagent [2,4-bis(4-methoxyphenyl)- 1,3-dithia-2,4-diphosphetane~-2,4-disulfide] at 50°C then at gradually increasing temperatures (15°C intervals, up to the reflux temperature) until TLC shows that reaction } is occurring. Heating is continued until essentially no starting material remains; then the mixture is cooled, filtered, evaporated and purified by chromatography to yield the desired product.
By following the procedure of Example 3, or modifications well known to one skilled in the art, other sulfur-containing analogs of the invention may be produced./
Example 4 “ 1,2-Dihydro-5-phenylfuro(2,3-c] [1,8] naphthyridin- 4 (5H) -one
Dissolve 3-n-butyl-4-hydroxy-l-phenyl-1,8- naphthyridin-2 (1H) -one (10 g) in CHCl, (1 L). Add a solution of Br, (1.74 mL, 5.43 g) in CH,Cl, (30 mL) slowly. Stir briefly after the addition, then wash with water and evaporate. Recrystallize the intermediate bromo-compound (3-bromo-3-n-butyl-1l-phenyl-1,8- naphthyridin-2,4 (1H) -dione) from CH,Cl,/diethyl ether/hexane and redissolve it in CH,Cl, (200 mL) and
CH4OH (75 mL). Add DBU (12 mL, about 3 equiv.) and stir : at room temperature. Evaporate off the solvents after about 1 hour and redissolve the residue in CH,Cl, (750 ’ mL). Add H,0 and adjust the aqueous layer to pH of about 4 with IN HCl. Dry with Mgs04 and evaporate.
Recrystallize the product (3-n-butyl-3-methoxy-l-phenyl- 1,8-naphthyridin-2,4 (1H) -dione) from diethyl ether /CH,C1, and purify, if necessary, by chromatography over silica gel, eluting with CH,Cl, containing 5% ethyl acetate.
Dissolve the purified product (5 g) in dry tetrahydrofuran (THF) (50 mL) and cool to below 0°C. Add a slight excess of vinyl magnesium bromide (1M in THF) and allow to react for 1 hour, then warm to room temperature. = Add aqueous NH4Cl solution (50 mL), . evaporate off the THF and extract into CH,C1, (2x50 mL). Wash with H,0 (2x50 mL), dry fwith Na,S0, and : evaporate to yield a mixture of diastereomeric alcohols (diastereomers of 3-n-butyl-4-ethenyl-4-hydroxy-3- ; methoxy-1l-phenyl-1,8-naphthyridin-2(1H)-one). oo Dissolve the mixture in CH,Cl, (50 mL) and cool to -78°C. Add a slight excess of BBrj in CH,Cl, (10 mL) and stir for 1 hour. Allow to warm to room temperature, add H,0 (25 mL) and adjust the pH of the aqueous layer to 4. Separate the organic layer, wash with water (2x25 - “ mL) , ary faith Na5504, and evaporate. Dissolve the crude . 1% product (3-n-butyl-4-ethenyl-3,4-dihydroxy-l-phenyl-1,8- ot naphthyridin-2(1H)-one) in cold CF4SO3H (below 0°C) (20 mL) and stir until reaction is complete, as shown by HPLC analysis of a small sample. Allow to warm to room temperature, then pour into ice-water, adjust the pH to 4 and extract with CHpClp (2x50 mL). Wash the organic layer with H,O0 (2x25 mL), dry with MgSO4, evaporate and
261,04 -36- purify by column chromatography over silica gel, eluting . with increasing concentrations of ethyl acetate in
CH,Cl,. Evaporate the fractions containing the product : and recrystallize to yield the desired product.
Example 5 1,2-Dihydro-2-(hydroxymethyl)-4~phenyl- cyclobuta(c)[1,8]naphthyridin-3(4H)-one
A solution of 4-(2-propenyloxy)-l-phenyl-1,8- naphthyridin-2(1H)-one (1.0 g) in methanol (350 mL) under an atmosphere of nitrogen was irradiated at 3000A for 34 days. Solvent was removed under vacuum and the reaction product purified by chromatography on silica gel in
CH,C1, containing 10% ethyl acetate. The fractions containing the product were combined and evaporated to yield 3(S R),9b(R S)-3,3a-dihydro-5-phenyl-3,9b-methano- 2H-furo[3,2-c] [1,8] naphthyridin-4(5H)~one, which was recrystallized from CH,Cl,/diethyl ether, m.p. 198- 199.5°C.
This compound (1.5 g) was dissolved in CH30H (100 mL). To the solution was added sodium methoxide (320 mg) and the mixture was heated at 90°C under a nitrogen atmosphere for about 2.5 hours. Solvent was removed under vacuum, the residue suspended in water, and the pH adjusted to 4 with IN HCl. The product was . extracted with CH,Cl, (3x100 mL) and the combined extracts washed with water (100 mL), dried with MgSOy. . and partially evaporated before separation on a silica gel chromatography column. The column was first eluted with CH,C1, containing 10% ethyl acetate, followed by
CH,Cl, containing 5% CH;0H, and the product isolated from the relevant fractions, m.p. 204-206°C.
’ Example 6 5-phenyl-8,9-dihydro-7H-cyclopentalc] [1,8] naphthyridin-6- (5H)-one 1/4 H,0 6a To a stirred mixture of the product of Example ’ 5, 1,2-dihydro-2-(hydroxymethyl)-4-phenyl- cyclobuta(c) (1,8) naphthyridin-3(4H)-one and triethylamine (0.2 mL) in CH,Cl, (5 mL) was added methanesulfonic anhydride (0.l14g) at room temperature. After 2 hours at room temperature an additional quantity of methanesulfonic anhydride (65 mg) was added. The reaction/was followed by TLC (silica gel/CH,Cl,:5%
MeOH). When the reaction was complete, the reaction . mixture was evaporated to dryness, redissolved in fresh
CH,Cl,, washed with 50 ml of H,0 adjusted to a pH of about 8, dried (MgSO4), and evaporated. . The crude mesylate (0.22) was dissolved in
CF3S03H (1 mL) at room temperature (in an No atmosphere). After 2 days at room temperature the solution was heated at 80°C for about 20 hours. After cooling, dilute NaOH solution was added and the mixture was adjusted to pH 4.5 with aqueous HCl solution. The product was extracted with CH,Cl, and this extract was washed with H,0, dried (MgSO), and evaporated to yield a mixture of the positonal double bond isomers. - 6b The mixture of double bond positional isomers from 6a (50 mg) was dissolved in MeOH (10 mL) containing ) AcOH (0.1 mL). To the solution was added ammonium formate (36 mg) and 5% Pd/C (25 mg). The mixture was stirred (in an N, atmosphere) at room temperature and was followed by TLC (silica gel/CH,Cl,:5% MeOH). Additional quantities (x2) of ammonium formate (36 mg) were added after stirring had progressed for 0.5 hours and 4 hours. After 25 hours the solution was diluted with
MeOH, filtered through Celite which was/washed with more
MeOH, and evaporated. The crude product was purified by chromatography (silica gel/CH,Cl,:5% MeOH) to yield the desired product, which was recrystallized from
Et,0/CH,Cl,, m.p. 230~232°C; yield 75%.
By the methods of Examples 1-5 using suitably substituted reagents, the compounds according to Table
III may be prepared.
39a
TABLE III
= cor fC i N N-NA (Rl-t-r2) : | 2
Q
Xx ny» n rR ga BW °
CH 0 - 0 - =- 0 ~CH,CH,CH,0- CgHg~ cH 0 - 0 - - 0 ~CH,CH,O- CgHg-
N 0 - 0 - =- 0 ~CH,CH,CH,CH,~ CgHg-
N 0 - 0 - - 0 ~CH,CH,CH,CHy~ 3-Cl-CgHy-
N 0 - 0 - =- 0 -CHpCH,CHpCHyO- CgHg—
N 0 - 0 - =- 0 ~CH,CH,CH,0- CgHs—
N 0 - o - =~ 0 -CH,CH,0- CgHsg-
CH 0 - 0 - =- s ~CHyCH,CH,CH)O- CgHg- : . CH 0 - 0 - - s ~CH,CH,CH,CHy- CeHs~
CH 1 7-CH; 0 - - © ~CHoCH,CH,0~ 4-CH30-CgHy-
CH 0 - 0 - - 0 ~CHyCH(OH)CHyO- ~~ CgHg-
CH 0 - 0 - - © —CH,CH(CH,0H)CHy~ CgHg-
CH 0 - 0 - - 0° ~CH,CH,CH(CH,0H)O- CgHg—
CH 0 - 0 - =- 0 ~CHCHyCH,CH,0~ 3-CH3S-CgH,-
CH 0 - 0 - - 0 ~CH,CH,CH,CHy~ 3-NO,~CgHy=
CH 0 - 0 - =~ 0 ~CH,CH,CHy= 3-Br-CgHy-
CH 0 - 1 H H 0 —CHyCH,CHyN(CH3)= 3-CF3-CgHy- ” CH 0 - 1 CH; H © ~CH,CH,CH- J \)
S
: CH 1 6Cl 1 H H 0 ~CH,CH,CH,~S* (0) CgHs-
CH 0 - 2 H H oO ~CH,CH,CH,0- 4-F-CgHy-
CH 0 - 1 H H © ~CH,CH,CH,CH,~
CH 0 - 1 H H O ~CH,CH,CH,0- 2
N
*Numbering based on 1,8-naphthyridine.
} The following formulations exemplify some of the dosage forms of the compositions of this invention.
In each, the term "active compound" designates 7-phenyl- 1,2,3,4-tetrahydro-oxepino(2,3-c}[1,8]-naphthyridin- - 6 (7H) -one. It is contemplated, however, that this compound may be replaced by equally effective amounts of } other compounds of formula I.
Pharmaceutical Dosage Form Examples
Example A
Tablets
No. Ingredient mg/tablet mg/tablet 1. Active compound 100 500 2. Lactose USP 122 113 3. Corn Starch, Food Grade, 30 40 as a 10% paste in
Purified Water 4. Corn Starch, Food Grade 45 40 - 5. Magnesium Stearate _3 _1
Total 300 700
Method of Manufacture
Mix Item Nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with Item No. 3. Mill the damp granules through a coarse screen (e.g., 1/4") if \ needed. Dry the damp granules. Screen the dried granules if needed and mix with Item No. 4 and mix for, 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. . Compress the mixture to appropriate size and weight on a suitable tablet machine.
LF
Example B
Capsules : No. Ingredient mg/capsule mg/capsule . 1. Active compound 100 500 2. Lactose USP 106 123 3. Corn Starch, Food Grade 40 70 . 4, Magnesium Stearate NF 4 7
Total 250 700
Method of Manufacture
Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.
Example C
Parenteral } Ingredient ’ mg/vial mg/vial :
Active Compound Sterile Powder 100 500
Add sterile water for injection or bacteriostatic water for injection, for reconstitution. - Example D
Injectable
Ingredient mg/vial - Active Compound 100
Methyl p-hydroxybenzoate 1.8
Propyl p-hydroxybenzoate 0.2 ” Sodium Bisulfite 3.2
Disodium Edetate 0.1
Sodium Sulfate 2.6
Water for Injection g.s. ad 1,0 ml
Method of Manufacture (for 1000 vials) 1. Dissolve p-hydroxybenzoate compounds in a portion (85% of the final volume) of the water for injection at 65-70°C. ji 2, Cool to 25-35°C. Charge and dissolve the sodium bisulfite, disodium edetate and sodium sulfate. . 3. Charge and dissolve active compound. 4, Bring the solution to final volume by added water for injection. 5S. Filter the solution through 0.22, membrane and fill into appropriate containers. 6. Finally sterilize the units by autoclaving.
Example E
Nasal Spray mg/ml
Active Compound 10.0
Phenyl Mercuric Acetate 0.02 : Aminoacetic Acid USP 3.7
Sorbitol Solution, USP 57.0
Benzalkonium Chloride Solution 0.2 ’ Sodium Hydroxide 1N Solution to ————— adjust pH
Water Purified USP to make 1.0 ml
The following formulations exemplify some of the dosage forms in which the anti-psoriatic agents of the invention may be employed. : Example F ’ Ointment ’ Formula mg/g
Active Compound 1.0-20.0
Benzyl Alcohol, NF 20.0
Mineral Oil, USP 50.0
White Petrolatum, USP to make 1.0 g
Method of Manufacture . Disperse active compound in a portion of the mineral oil. Mix and heat to 65°C, a weighed quantity of white petrolatum, the remaining mineral 0il/and benzyl } alcohol, and cool to 50°-55°C. with stirring. Add the dispersed active compound to the above mixture with stirring. Cool to room temperature.
Example G
Cream
Formula mg/g
Active Compound 1.0-20.0
Stearic Acid, USP 60.0
Glyceryl Monostearate 100.0
Propylene Glycol, USP 50.0
Polyethylene Sorbitan Monopalmitate 50.0
Sorbitol Solution, USP 30.0 ) Benzyl Alcohol, NF 10.0 : Purified Water, USP to make 1.0 g
Method of Manufacture
Heat the stearic acid, glyceryl monostearate and polyethylene sorbitan monopalmitate to 70°C. In a
Separate vessel, dissolve sorbital solution, benzyl alcohol, water, and half quantity of propylene glycol and heat to 70°C. Add the aqueous phase to oil phase with high speed stirring. Dissolve the active compound in remaining quantity of propylene glycol and add to the above emulsion when the temperature of emulsion is 37°- ’ 40°C. Mix uniformly with/stirring and cool to room . temperature.
Example H
Gel
Formula mg./g
Active Compound 1.0-20.0 : Propylene Glycol, USp 300.0
Butylated Hydroxytoluene 5.0
Carbomer 940 5.0
Sodium Hydroxide (added as a 1% w/w solution in propylene glycol) 0.7
Polyethylene Glycol 400, USP 669.3~-688.
Method of Manufacture
Prepare a 1% solution of the sodium hydroxide in propylene glycol. Add approximately one-half the remaining propylene glycol and the polyethylene glycol . 400 to a suitable vessel and mix. Dissolve the butylated hydroxytoluene in this mixture. Disperse Carbomer 940, a polymer of acrylic acid crosslinked with a polyfunctional agent, in the above mixture with vigorous agitation. add the solution of sodium hydroxide with high speed agitation to bring pH up to 7 and mix until a thick gel forms. Dissolve the active compound in the remaining propylene glycol and add to the gel slowly as the gel is continuously mixed./
Example I , Lotion . Formula mg/g
Active Compound 1.0-20.0
Carbomer 940 3.0
Sodium hydroxide (charged as 4% w/w 0.05 aqueous solution)
Isopropyl Alcohol 40.00
Purified Water, USP to make 1.0 g
Method of Manufacture
Prepare a 4% solution of sodium hydroxide in water. Heat the purified water to 60°C. Add Carbomer 940 and mix at high speed until dispersed. Cool the above mixture to room temperature and slowly charge . sodium hydroxide solution until uniform. Add 80% of isopropyl alcohol to the above with mixing. Dissolve the active compound in remaining isopropyl alcohol. Add this to the mixture with stirring. Adjust PH to 5.0 to 5.5 with sodium hydroxide, if necessary./
Example J
Topical Aerosol
Formula mg/g
Active Compound 1.0-20.0 ’ Caprylic/Capric Triglyceride 50.00
Mineral 0il 20.00
Denatured Alcohol 150.00
Hydrocarbon Aerosol Propellant d.s. ad. 1.0 g
Method of Manufacture
Add and mix the caprylic/capric triglyceride mineral oil and specially denatured alcohol in a suitable compounding tank. Add the active compound and continue mixing until the active compound is dissolved or . dispersed uniformly. Fill the concentrate into cans and then fill the required amount of hydrocarbon aerosol propellant.
-46—~
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in . the art. All such alternatives, modifications and variations are intended to fall within the spirit and : scope of the present invention. ‘
. . , « ' -53-
ABSTRACT OF THE DISCLOSURE
! Aryl-substituted naphthyridines and pyrido- pyrazines are disclosed which are useful in treating allergic reactions, inflammation, peptic ulcers, hyperproliferative skin disease and/or suppressing immune responses in mammals. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed. ~ \
CN
. ih
P/PASP1030
Claims (13)
- CLAIMS! 1, A compound having the atructural formula I B 0(x). | i I UN A “A (==, Q and pharmaceutically acceptable salts thereof, where in: X represents CH or Nj A represents O or 53% m is an integer of from O to 2% n ia an integer of from O to 2; rR! and rR? are the same or different and each : is independently selected from H and alkylj W represents a covalent bond or a group selected from -O-, ~8(0) - and -N(RY)- (wherein p is an integer of from O to 2 and g is alkyl having 1 to 4 carbon atoms); B is selected from alkylene having from 2 to 8 carbon atoms, which alkylene may be optionally1 —————————— ——— + — substituted with a group selected from -OH, ~F, and ~CH, 0H, with the proviso that OH or F is not on the carbon adjacent to W when W is selected from -Oe -8(0) - and -N(RY)-, and unsubstituted alkylene have ing from 2 to 8 carbon atoms and one or more double bonds Q represents an aryl group selected from phenyl and naphthyl or an aromatic monocyclic heterocyclic group selected from pyridyl and thienyl, each of which can optionally be substituted with one substi- tuent Y as defined below; and each Y substituent is independently selected from ~OH, hydroxymethyl, alkyl having 1 to 4 carbon atoms, halo, =NO,, alkoxy having 1 to 4 carbon atoms, ~CF, and -s-g" wherein Rg? is as defined above.
- 2. The compound of Claim 1 having the formula SB { \ ; vw a. Prd ' PN 3 (0, | ] | 11 Sa ~~ nN N | A w=} — l
- 2. wherein A, B, W, Y and n are as defined in Claim 1 and q is 0 or 1, and wherein, if n + q is greater than 1, the Y groups may be the same or different, 3e The compound of Claim 2 wherein: -B-W- represents an alkylene group or an al- kylenoxy group either of which may be substituted; said alkylene and alkylenoxy group having from 2 to 8 carbon atoms and the substituents thereof are as defined in Claim 1.
- 4, The compound of Claim 2 wherein B~-W represents =(CH,) =o -(CH,) c= -(CH,),~0= or -(CH,) 4-0; and n is zero.
- Se The compound of Claim 2 wherein: A is oxygen and the Y substituent on the phenyl ring is selected from independently chloro, nitro and trifluoromethyl.
- 6. A compound according to Claim 1, namely 5-phenyl-7,8,9,10-tetrahydro-benzo/c 7/T,8/~ naphthyridin-6(5H)~one.
- Te A compound according to Claim 1, namely S=(3-chlorophenyl)-7,8,9,10=tetrahydro~benzo- [<_7/1,8/-naphthyridin-6(5i)=-one.
- 8. A compound according to Claim 1, namely
- 7-phenyl-1,2,3,4=tetrahydro-oxepino/2, 3-c/= /1:8/-naphthyridin-6(7H)-one. LS A compound according to Claim 1, namely 7-(3-chlorophenyl)=-1,2,3,4=-tetrahydro-oxepino- [2+3-c//T,8/-naphthyridin-6-(7H)=one.
- 10. A pharmaceuticel composition which comprises a compound as defined ih Claim 1 in combination with a pharmaceutically acceptable carrier.
- 11. A method for treating allergic reactions in a mammal which comprises administering an anti-allergic effective amount of the pharmaceutical composition defined in Claim 10 to said mammal.
- 12. A method for treating inflammation in a mammal which comprises administering an anti-inflammatory effective amount of the pharmaceutical composition defined in Claim 10 to said mammal,
- 13. A method for treating hyperproliferative skin diseases in a mammal which comprises topically ad- ministering an effective amount of a pharmaceutical composition defined in Claim 10 to said mammal. DAVID J. BLYTHIN MARVIN I. SIEGEL HO=~JANE SHUE SIDNEY R. SMITH Inventors
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85106886A | 1986-04-11 | 1986-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26104A true PH26104A (en) | 1992-02-06 |
Family
ID=25309887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH35116A PH26104A (en) | 1986-04-11 | 1987-04-09 | Aryl-substituted naphthyridine and pyrodopyrazine derivatives |
Country Status (2)
Country | Link |
---|---|
PH (1) | PH26104A (en) |
ZA (1) | ZA872566B (en) |
-
1987
- 1987-04-09 PH PH35116A patent/PH26104A/en unknown
- 1987-04-09 ZA ZA872566A patent/ZA872566B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA872566B (en) | 1987-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4450164A (en) | Imidazo[1,2-A]pyridines and use | |
AU651353B2 (en) | Pyrazolopyridine compound and processes for preparation thereof | |
EP0232328B1 (en) | Zwitterionic bicyclic compounds and their salts, solvates, hydrates and esters | |
JPH05507092A (en) | Bis-benzo or benzopyridocycloheptapiperidine, piperidylidene and piperazine compounds and compositions | |
US4760073A (en) | Aryl-substituted naphthyridine and pyridopyrazine derivatives, useful as anti-allergic agents | |
US5037826A (en) | 1-substituted naphthyridine and pyridopyrazine derivatives | |
IE61740B1 (en) | 6,11-Dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta [1,2-b]pyridines and compositions and methods of use | |
KR850000380B1 (en) | Process for preparation of imidazol derivatives | |
US4652564A (en) | Substituted spiro pyridine derivatives as anti-allergy and antiinflammatory agents | |
AU617672B2 (en) | Aryl substituted naphthalene, benzoxepine, benzazepine, benzocycloheptene derivatives | |
EP0267691A2 (en) | Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity. | |
EP0229823B1 (en) | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives | |
CA1324381C (en) | Aryl-substituted naphthyridine and pyridopyrazine derivatives | |
US5011860A (en) | Aryl-substituted naphthyridine and pyridopyrazine derivatives and their use in treating hyperproliferative skin diseases | |
US4775686A (en) | Naphthyridine derivatives and method for treating allergic reactions | |
PH26104A (en) | Aryl-substituted naphthyridine and pyrodopyrazine derivatives | |
JPS63159382A (en) | 1-substituted naphthilidine and pyridopyradine derivative | |
GB2153348A (en) | Substituted spiro pyridine derivatives | |
US4882332A (en) | Immune suppression method employing arly-substituted naphthyridine and pyridopyrazine derivatives | |
US4740511A (en) | Method of treating hyperproliferative skin disease | |
US4916131A (en) | Naphthyridine derivatives and method for treating allergic reactions | |
EP0362299A1 (en) | Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation | |
US4775524A (en) | Method of treating hyperproliferative skin disease with substituted heterospiro pyridine derivatives | |
US4859669A (en) | Antiinflammatory and anti-hyperproliferative naphthyridin-4-ones | |
US4996212A (en) | Antiinflammatory and anti-hyperproliferative compounds |